近五分之一的非小细胞肺癌（NSCLC）患者会发生肝转移（LM），肝转移的整体治疗策略将直接影响患者的生存。然而，一些回顾性研究发现，接受化疗或靶向治疗的患者一旦出现LM，预后较差。近年来，多项随机对照试验（RCTS）显示，与传统化疗相比，引入免疫检查点抑制剂（ICIs）后晚期肺癌患者的预后显着改善。尽管 LM 患者在随机临床试验中代表性不足，但 ICI 对 LM 患者是安全有效的。然而，接受ICIs治疗时，带有LMs的NSCLC患者的预后明显差于没有LMs的患者，并且LMs引起全身抗肿瘤免疫降低的机制尚不清楚，因此NSCLC患者中LMs的管理是一个临床挑战。需要更优化的治疗方法来实现有效的疾病控制。在这篇综述中，我们总结了ICIs治疗LM的机制、ICIs的临床研究和治疗进展以及ICIs与其他疗法联合治疗NSCLC LM的情况。© 2023。作者。

Nearly one-fifth of patients with non-small cell Lung Cancer (NSCLC) will develop liver metastases (LMs), and the overall treatment strategy of LMs will directly affect the survival of patients. However, some retrospective studies have found that patients receiving chemotherapy or targeted therapy have a poorer prognosis once LMs develop. In recent years, multiple randomised controlled trials (RCTS) have shown significant improvements in outcomes for patients with advanced lung cancer following the introduction of immune checkpoint inhibitors (ICIs) compared to conventional chemotherapy. ICIs is safe and effective in patients with LMs, although patients with LMs are mostly underrepresented in randomised clinical trials. However, NSCLC patients with LMs have a significantly worse prognosis than those without LMs when treated with ICIs, and the mechanism by which LMs induce systemic anti-tumour immunity reduction is unknown, so the management of LMs in patients with NSCLC is a clinical challenge that requires more optimised therapies to achieve effective disease control. In this review, we summarised the mechanism of ICIs in the treatment of LMs, the clinical research and treatment progress of ICIs and their combination with other therapies in patients with LMs from NSCLC.© 2023. The Author(s).